EP1479382A1 — Oral pharmaceutical compositions containing taxanes and methods for treatment employing the same
Assigned to Ivax Research Holdings Inc · Expires 2004-11-24 · 21y expired
What this patent protects
Pharmaceutical compositions for oral administration to mammalian subjects comprise a taxane or taxane derivative (e.g. paclitaxel or docetaxel) as active ingredient and a vehicle comprising at least 30% by weight of a carrier for the taxane, said carrier having an HLB value of at…
USPTO Abstract
Pharmaceutical compositions for oral administration to mammalian subjects comprise a taxane or taxane derivative (e.g. paclitaxel or docetaxel) as active ingredient and a vehicle comprising at least 30% by weight of a carrier for the taxane, said carrier having an HLB value of at least about 10. The compositions may also comprise 0 - 70% of a viscosity-reducing co-solubilizer. The compositions may be incorporated into conventional oral pharmaceutical dosage forms, or can be in the form of a two-part medicament wherein the first part includes the taxane in a solubilizing vehicle and the second part comprises a carrier for the taxane to promote oral absorption. Methods of treatment of taxane-responsive disease conditions employing the novel compositions are also disclosed, whereby the compositions can be administered alone or in association with an oral bioavailability enhancing agent.
Drugs covered by this patent
- Taxotere (Docetaxel) · Sanofi
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.